Regeneron Pharmaceuticals
(NQ:
REGN
)
1,052.25
+18.02 (+1.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
366,219
Open
1,039.51
Bid (Size)
1,052.25 (1)
Ask (Size)
1,057.00 (1)
Prev. Close
1,034.23
Today's Range
1,037.32 - 1,054.60
52wk Range
688.52 - 1,081.17
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 No-Brainer Stocks to Buy in July
Today 8:00 EDT
Investors shouldn't have to think too hard about these great stocks.
Via
The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Today 6:00 EDT
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
Via
InvestorPlace
Performance
YTD
+16.27%
+16.27%
1 Month
+5.04%
+5.04%
3 Month
+12.12%
+12.12%
6 Month
+16.54%
+16.54%
1 Year
+49.60%
+49.60%
More News
Read More
The 3 Best Biotech Stocks to Buy in July 2024
July 05, 2024
Via
InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
Via
Investor's Business Daily
7 High Priced Stocks That Would Benefit From a Stock Split
July 04, 2024
Via
InvestorPlace
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
July 04, 2024
Via
Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
July 02, 2024
Via
Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
June 25, 2024
Via
Benzinga
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
July 03, 2024
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
June 28, 2024
Via
Benzinga
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
June 28, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
June 24, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
June 20, 2024
Via
Benzinga
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
June 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
June 27, 2024
Via
Benzinga
Exposures
Product Safety
3 Biotech Stocks That Could Make Your Grandchildren Rich
June 27, 2024
Via
InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
June 24, 2024
Via
Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
June 24, 2024
Via
Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Via
Benzinga
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
June 21, 2024
Via
InvestorPlace
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
June 13, 2024
Via
Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.